

Andrzej J Budaj

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5456324/andrzej-j-budaj-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

163
papers

49,250
citations

64
h-index

170
g-index

170
ext. papers

57,247
ext. citations

10.7
avg, IF

6.47
L-index

#	Paper	IF	Citations
163	Impact of COVID-19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV-HF-SIRIO 6 study). <i>ESC Heart Failure</i> , 2021 , 9, 721	3.7	3
162	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. <i>Cardiology Journal</i> , 2021 ,	1.4	1
161	Prognostic value of galectin-3 and right ventricular function for long-term mortality in heart failure patients treated with cardiac resynchronization therapy. <i>Scientific Reports</i> , 2021 , 11, 21390	4.9	
160	Risk markers of incident atrial fibrillation in patients with coronary heart disease. <i>American Heart Journal</i> , 2021 , 233, 92-101	4.9	4
159	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021 , 44, 1219-1227	14.6	9
158	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , 2021 , 143, 2129-2142	16.7	14
157	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021 , 384, 117-128	59.2	408
156	Pregnancy Outcomes in Women After Arterial Switch Operation for Transposition of the Great Arteries: Results From ROPAC (Registry of Pregnancy and Cardiac Disease) of the European Society of Cardiology EURObservational Research Programme. <i>Journal of the American Heart Association</i> , 2021 , 10, e018176	6	4
155	The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 28-33	4.6	1
154	Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. <i>Heart</i> , 2021 , 107, 1739-1747	5.1	5
153	Antiplatelets in acute coronary syndrome in Poland - from guidelines to clinical practice. <i>Postępy W Kardiologii Interwencyjnej</i> , 2021 , 17, 141-154	0.4	0
152	Chronotropic Incompetence Limits Aerobic Exercise Capacity in Patients Taking Beta-Blockers: Real-Life Observation of Consecutive Patients. <i>Healthcare (Switzerland)</i> , 2021 , 9,	3.4	2
151	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021 , 10, e017008	6	6
150	A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. <i>Cardiology Journal</i> , 2021 , 28, 607-614	1.4	2
149	Combined use of stress echocardiography and cardiopulmonary exercise testing to assess exercise intolerance in patients treated for acute myocardial infarction. <i>PLoS ONE</i> , 2021 , 16, e0255682	3.7	1
148	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. <i>JAMA Cardiology</i> , 2021 ,	16.2	5
147	Mechanisms of Exercise Capacity Improvement after Cardiac Rehabilitation Following Myocardial Infarction Assessed with Combined Stress Echocardiography and Cardiopulmonary Exercise Testing. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1

146	Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e020446	6	1
145	Comparative Efficacy and Safety of Oral P2Y Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials. <i>Circulation</i> , 2020 , 142, 150-160	16.7	44
144	A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. <i>American Heart Journal</i> , 2020 , 227, 56-63	4.9	6
143	Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 449-456	7	5
142	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2020 , 141, 1227-1234	16.7	97
141	Professor Leszek Ceremuga (1932-2009): a prominent figure in Polish cardiology. <i>Kardiologia Polska</i> , 2020 , 78, 263-264	0.9	
140	Cardiac tamponade as a complication of pancreaticopericardial fistula. <i>Kardiologia Polska</i> , 2020 , 78, 932-933	0.3	
139	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <i>Cardiology Journal</i> , 2020 , 27, 661-676	1.4	4
138	TransRadial versus transUlnar artery approach for elective invasive percutaneous coronary interventions: a randomized trial on the feasibility and safety with ultrasonographic outcome - RAUL study. <i>Postepy W Kardiologii Interwencyjnej</i> , 2020 , 16, 376-383	0.4	
137	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2020 , 41, 1625-1632	9.5	19
136	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. <i>Atherosclerosis</i> , 2020 , 293, 35-41	3.1	2
135	Assessment of quality of care of patients with ST-segment elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 893-901	4.3	4
134	Galectin-3 is related to right ventricular dysfunction in heart failure patients with reduced ejection fraction and may affect exercise capacity. <i>Scientific Reports</i> , 2020 , 10, 16682	4.9	4
133	Impact of the Use of a Larger Forearm Artery on the Efficacy and Safety of Transradial and Transulnar Access: A Randomized Trial with Preprocedural Ultrasonography. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
132	Younger age of patients with myocardial infarction is associated with a higher number of relatives with a history of premature atherosclerosis. <i>BMC Cardiovascular Disorders</i> , 2020 , 20, 410	2.3	2
131	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels American Heart Journal, 2020 , 225, 97-107	4.9	1
130	Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 563-569	5.1	6
129	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2019 , 140, 1960-1963	16.7	6

128	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019 , 380, 1509-1524	59.2	538
127	Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. <i>Journal of the American Heart Association</i> , 2019 , 8, e011139	6	20
126	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 618-628	18.1	120
125	Transvenous lead extraction procedures in women based on ESC-EHRA EORP European Lead Extraction ConTROLLED ELECTRa registry: is female sex a predictor of complications?. <i>Europace</i> , 2019 , 21, 1890-1899	3.9	1
124	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005858	5.8	13
123	Smoking and cardiovascular diseases: paradox greater than expected?. <i>Polish Archives of Internal Medicine</i> , 2019 , 129, 700-706	1.9	4
122	Improvement of left ventricular function after percutaneous coronary intervention in patients with stable coronary artery disease and preserved ejection fraction: Impact of diabetes mellitus. <i>Cardiology Journal</i> , 2019 ,	1.4	1
121	A novel technique for iatrogenic pseudoaneurysm obliteration with ultrasound-guided thrombin foam injection. <i>Vasa - European Journal of Vascular Medicine</i> , 2019 , 48, 181-184	1.9	1
120	Significant left ventricular outflow tract obstruction observed during postexercise verticalization in a symptomatic patient with hypertrophic cardiomyopathy. <i>Kardiologia Polska</i> , 2019 , 77, 655-656	0.9	
119	Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future. <i>European Heart Journal</i> , 2019 , 40, 1728-1738	9.5	3
118	Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. <i>American Heart Journal</i> , 2019 , 208, 65-73	4.9	7
117	Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 473-480	16.2	21
116	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2018 , 39, 213-260	9.5	1475
115	ESR2 gene G1730A variant is associated with triglycerides level and myocardial infarction in young men but not in women. <i>Gene</i> , 2018 , 677, 83-88	3.8	1
114	Response to "Acetazolamide and Cardiac Failure". <i>Clinical Drug Investigation</i> , 2018 , 38, 651	3.2	1
113	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2018 , 379, 1107-1117	59.2	143
112	Exercise left ventricular outflow tract obstruction as a cause of exercise intolerance: combined stress echocardiography and cardiopulmonary exercise testing. <i>Kardiologia Polska</i> , 2018 , 76, 1492	0.9	1
111	Adiponectin gene variants and decreased adiponectin plasma levels are associated with the risk of myocardial infarction in young age. <i>Gene</i> , 2018 , 642, 498-504	3.8	10

110	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet, The</i> , 2018 , 391, 319-328	40	430
109	Electrocardiographic Findings in Patients With Acute Coronary Syndrome Presenting With Out-of-Hospital Cardiac Arrest. <i>American Journal of Cardiology</i> , 2018 , 121, 294-300	3	4
108	Echocardiographic predictors of exercise intolerance in patients with heart failure with severely reduced ejection fraction. <i>Medicine (United States)</i> , 2018 , 97, e11523	1.8	5
107	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. <i>Journal of the American Heart Association</i> , 2018 , 7, e009260	6	7
106	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 392, 2269-2279	40	46
105	Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). <i>American Journal of Cardiology</i> , 2018 , 122, 944-951 ³		7
104	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. <i>American Heart Journal</i> , 2017 , 186, 91-99	4.9	24
103	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. <i>Clinical Chemistry</i> , 2017 , 63, 325-333	5.5	62
102	Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	105
101	Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: a Pilot Study. <i>Clinical Drug Investigation</i> , 2017 , 37, 1175-1181	3.2	25
100	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. <i>International Journal of Cardiology</i> , 2017 , 245, 271-276	3.2	15
99	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 813-826	15.1	58
98	Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor. <i>Kardiologia Polska</i> , 2017 , 75, 614	0.9	1
97	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2016 , 37, 267-315	9.5	3850
96	Right ventricular systolic function as a marker of prognosis after ST-elevation inferior myocardial infarction 5-year follow-up. <i>International Journal of Cardiology</i> , 2016 , 221, 549-53	3.2	9
95	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. <i>JAMA Cardiology</i> , 2016 , 1, 425-32	16.2	70
94	Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	36
93	Tooth loss is independently associated with poor outcomes in stable coronary heart disease. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 839-46	3.9	28

92	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2016 , 37, 1133-42	9.5	103
91	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. <i>International Journal of Cardiology</i> , 2016 , 218, 291-297	3.2	5
90	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1591-9	27.4	144
89	Long-term use of ticagrelor in patients with prior myocardial infarction. <i>New England Journal of Medicine</i> , 2015 , 372, 1791-800	59.2	1193
88	Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. <i>American Journal of Medicine</i> , 2015 , 128, 766-75	2.4	58
87	High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2015 , 36, 976-83	9.5	42
86	Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors. <i>European Journal of Preventive Cardiology</i> , 2015 , 22, 771-8	3.9	35
85	Darapladib for preventing ischemic events in stable coronary heart disease. <i>New England Journal of Medicine</i> , 2014 , 370, 1702-11	59.2	363
84	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATElet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2014 , 35, 1541-50	9.5	53
83	Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1493-9	15.1	39
82	Guía de Práctica Clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable. <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 135.e1-135.e81	1.5	9
81	Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATElet inhibition and patient Outcomes study. <i>American Heart Journal</i> , 2014 , 168, 96-102.e2	4.9	15
80	Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock. <i>Heart</i> , 2014 , 100, 1456-61	5.1	2
79	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. <i>Circulation</i> , 2013 , 128, 237-43	16.7	166
78	Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2013 , 166, 290-7	4.9	13
77	Effect of radial versus femoral access on radiation dose and the importance of procedural volume: a substudy of the multicenter randomized RIVAL trial. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 258-65	5	99
76	Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST. <i>Revista Espanola De Cardiologia</i> , 2013 , 66, 53.e1-53.e46	1.5	17
75	Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATElet Inhibition and Patient Outcomes (PLATO) study. <i>Clinical Chemistry</i> , 2013 , 59, 1369-75	5.5	17

74	2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. <i>European Heart Journal</i> , 2013 , 34, 2949-3003	9.5	3076
73	Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study. <i>European Heart Journal</i> , 2013 , 34, 993-1001	9.5	31
72	Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2490-9	15.1	296
71	Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. <i>Stroke</i> , 2012 , 43, 2221-7	6.7	70
70	Risk-prediction model for ischemic stroke in patients hospitalized with an acute coronary syndrome (from the global registry of acute coronary events [GRACE]). <i>American Journal of Cardiology</i> , 2012 , 110, 628-35	3	10
69	Right ventricular dysfunction and exercise capacity after inferior (posterior) wall acute myocardial infarction. <i>American Journal of Cardiology</i> , 2012 , 110, 784-9	3	7
68	Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. <i>American Heart Journal</i> , 2012 , 164, 728-34	4.9	8
67	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012 , 33, 2569-619	9.5	3978
66	Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. <i>Clinical Chemistry</i> , 2012 , 58, 190-9	5.5	34
65	Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials. <i>European Heart Journal</i> , 2012 , 33, 51-60	9.5	49
64	Apixaban in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 364, 806-17	59.2	1772
63	Design and rationale of the radial versus femoral access for coronary intervention (RIVAL) trial: a randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. <i>American Heart Journal</i> , 2011 , 161, 254-260.e1-4	4.9	40
62	Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2011 , 161, 878-85	4.9	6
61	Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. <i>Lancet, The</i> , 2011 , 377, 1409-20	4.9	1350
60	Myocardial ischemia and ventricular tachycardia on continuous electrocardiographic monitoring and risk of cardiovascular outcomes after non-ST-segment elevation acute coronary syndrome (from the MERLIN-TIMI 36 Trial). <i>American Journal of Cardiology</i> , 2011 , 108, 1373-81	3	12
59	Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. <i>European Heart Journal</i> , 2011 , 32, 581-9	9.5	153
58	Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. <i>European Heart Journal</i> , 2011 , 32, 2781-9	9.5	411
57	Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2011 , 32, 2933-44	9.5	262

56	Efficacy and safety of closing postcatheterisation pseudoaneurysms with ultrasound-guided thrombin injections using two approaches: bolus versus slow injection. A prospective randomised trial. <i>Kardiologia Polska</i> , 2011 , 69, 898-905	0.9	9
55	The diagnostic and prognostic value of right ventricular myocardial velocities in inferior myocardial infarction treated with primary percutaneous intervention. <i>Kardiologia Polska</i> , 2011 , 69, 1054-61	0.9	4
54	Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 1339-49	27.4	130
53	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <i>European Heart Journal</i> , 2010 , 31, 2133-40	9.5	26
52	Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. <i>European Heart Journal</i> , 2010 , 31, 50-8	9.5	64
51	Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb Therapy) comparing darapladib versus placebo in patients with coronary heart disease. <i>American Heart Journal</i> , 2010 , 160, 655-61	4.9	97
50	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet, The</i> , 2010 , 376, 1233-43	4.0	624
49	Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. <i>Circulation</i> , 2010 , 122, 1056-67	16.7	280
48	A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study. <i>European Heart Journal</i> , 2010 , 31, 1132-41	9.5	46
47	Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events). <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 26-33	5	60
46	Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. <i>American Heart Journal</i> , 2009 , 157, 502-8	4.9	22
45	Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , 2009 , 157, 1097-105	4.9	60
44	The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. <i>American Heart Journal</i> , 2009 , 158, 193-201.e1-5	4.9	145
43	Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 1411-21	15.1	39
42	Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , 2009 , 361, 1045-57	59.2	4753
41	In-hospital outcomes associated with fibrinolytic and thienopyridine use in patients with ST-segment elevation acute myocardial infarction. The global registry of acute coronary events. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009 , 62, 501-9	0.7	1
40	Evolució hospitalaria asociada al empleo de fibrinolíticos y tienopiridinas en pacientes con infarto agudo de miocardio y elevació del segmento ST. The Global Registry of Acute Coronary Events. <i>Revista Espanola De Cardiologia</i> , 2009 , 62, 501-509	1.5	1
39	Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2009 , 30, 186-95	9.5	153

38	Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. <i>European Heart Journal</i> , 2009 , 30, 655-61	9.5	121
37	Usefulness of quantitative versus qualitative ST-segment depression for risk stratification of non-ST elevation acute coronary syndromes in contemporary clinical practice. <i>American Journal of Cardiology</i> , 2008 , 101, 919-24	3	11
36	Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. <i>Circulation</i> 2008 , 118, 2038-46	16.7	76
35	Resistance to oral antiplatelet drugs--a Position Paper of the Working Group on antiplatelet drug resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society. <i>Kardiologia Polska</i> , 2008 , 66, 470-6, 480-5	0.9	3
34	Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1742-51	15.1	203
33	Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). <i>American Journal of Cardiology</i> , 2007 , 100, 1-6	3	99
32	Differences between local hospital and core laboratory interpretation of the admission electrocardiogram in patients with acute coronary syndromes and their relation to outcome. <i>American Journal of Cardiology</i> , 2007 , 100, 169-74	3	16
31	Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1775-83	27.4	372
30	Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1892-900	27.4	624
29	Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?. <i>Circulation</i> , 2007 , 116, 2793-801	16.7	182
28	Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. <i>American Heart Journal</i> , 2007 , 153, 493-9	4.9	14
27	Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST elevation acute coronary syndromes. <i>American Heart Journal</i> , 2007 , 154, 71-8	4.9	71
26	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2007 , 28, 1598-660	9.5	1438
25	Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1519-30	27.4	685
24	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). <i>European Heart Journal</i> , 2006 , 27, 1875-2030	9.5	479
23	ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). <i>Circulation</i> , 2006 , 114, 2551-670	16.7	1653
22	Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. <i>European Heart Journal</i> , 2006 , 27, 1341-81	9.5	981
21	Comparison of fondaparinux and enoxaparin in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2006 , 354, 1464-76	59.2	922

20	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). <i>Circulation</i> , 2006 , 114, 107-147	15.1	865
19	The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2006 , 151, 654-60	4.9	88
18	Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2006 , 151, 1123-8	4.9	68
17	Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study. <i>BMJ, The</i> , 2005 , 330, 441	5.9	78
16	Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2005 , 150, 1107	4.9	31
15	Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: findings from a Global Registry of Acute Coronary Events. <i>Circulation</i> , 2005 , 111, 3242-7	16.7	81
14	Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. <i>European Heart Journal</i> , 2004 , 25, 166-81	9.5	245
13	A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 291, 2727-33	27.4	1064
12	Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). <i>Circulation</i> , 2004 , 109, 494-9	16.7	369
11	Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. <i>Chest</i> , 2004 , 126, 461-9	5.3	342
10	Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. <i>Lancet, The</i> , 2004 , 364, 937-52	40	7508
9	Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2003 , 146, 999-1006	4.9	83
8	From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). <i>European Heart Journal</i> , 2003 , 24, 1414-24	9.5	173
7	Early and late effects of clopidogrel in patients with acute coronary syndromes. <i>Circulation</i> , 2003 , 107, 966-72	16.7	250
6	Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). <i>American Journal of Cardiology</i> , 2002 , 89, 791-6	3	235
5	Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. <i>Circulation</i> , 2002 , 106, 1622-6	16.7	192
4	Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). <i>Lancet, The</i> , 2002 , 359, 373-7	40	423
3	Stroke in relation to cardiac procedures in patients with non-ST-elevation acute coronary syndrome: a study involving >18 000 patients. <i>Circulation</i> , 2001 , 104, 269-74	16.7	50

2	Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. <i>Circulation</i> , 2000 , 102, 1014-9	16.7	598
1	Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. <i>Lancet, The</i> , 1998 , 352, 507-14	40	291